Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12590
Title: The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.
Austin Authors: Vella, Laura J;Andrews, Miles C;Pasam, Anupama;Woods, Katherine;Behren, Andreas;Cebon, Jonathan S 
Affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia
Issue Date: 3-Jul-2014
Publication information: Oncoimmunology 2014; 3(7): e946367
Abstract: Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.
Gov't Doc #: 25610732
URI: http://ahro.austin.org.au/austinjspui/handle/1/12590
DOI: 10.4161/21624011.2014.946367
URL: https://pubmed.ncbi.nlm.nih.gov/25610732
Type: Journal Article
Subjects: BRAF
MEK
T-lymphocytes
dendritic cells
melanoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Nov 29, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.